SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-08-052916
Filing Date
2008-03-11
Accepted
2008-03-11 16:16:52
Documents
6
Period of Report
2007-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d10k.htm 10-K 808433
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM dex231.htm EX-23.1 1701
3 CERTIFICATION BY THE CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 dex311.htm EX-31.1 7271
4 CERTIFICATION BY THE CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934 dex312.htm EX-31.2 7413
5 CERTIFICATION BY THE CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002 dex321.htm EX-32.1 2757
6 CERTIFICATION BY THE CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002 dex322.htm EX-32.2 2805
  Complete submission text file 0001193125-08-052916.txt   831872
Mailing Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277
Business Address 13950 BALLANTYNE CORPORATE PLACE UNIT 325 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Filer) CIK: 0001333763 (see all company filings)

IRS No.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51462 | Film No.: 08680792
SIC: 2836 Biological Products, (No Diagnostic Substances)